Do you have to know HbA1c for NCLEX? The short answer is yes — HbA1c is a core concept in diabetes nursing and appears regularly in examination questions. HbA1c, or glycated haemoglobin, reflects average blood glucose control over two to three months and is central to diagnosing diabetes, evaluating treatment, and guiding patient education. For nursing candidates, understanding HbA1c threshold values, clinical limitations, and associated nursing actions is essential for answering NCLEX-style questions with confidence and for delivering safe, evidence-based diabetes care in practice.

What Is HbA1c and Why It Matters in Diabetes Care

HbA1c measures average blood glucose over 2–3 months; a result of 48 mmol/mol (6.5%) or above is diagnostic of diabetes and guides treatment decisions, making it fundamental to nursing practice.

HbA1c, or glycated haemoglobin, is a blood test that reflects the average blood glucose concentration over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin within red blood cells — a process known as glycation. Because red blood cells have a lifespan of approximately 120 days, the HbA1c result provides a reliable long-term picture of glycaemic control, unlike a single fasting glucose reading which only captures a snapshot in time.

In clinical practice, HbA1c is expressed as a percentage or in millimoles per mole (mmol/mol), with the latter being the standard unit used in the United Kingdom. According to NICE guidelines (NG28) and WHO 2011 guidance, an HbA1c of 48 mmol/mol (6.5%) or above is diagnostic of diabetes in appropriate clinical contexts. In asymptomatic adults, the result must be confirmed with a second venous sample using a quality-assured, IFCC-standardised laboratory method — point-of-care HbA1c devices must not be used for diagnosis.

It is important to note that HbA1c is not appropriate for diagnosing diabetes in the following situations:

• Children and young people

• Pregnancy (including gestational diabetes)

• Suspected type 1 diabetes or acute-onset hyperglycaemia

• Conditions that alter red blood cell turnover, such as haemolytic anaemia, haemoglobinopathies (e.g., sickle cell disease), or chronic kidney disease

In these circumstances, fasting plasma glucose or an oral glucose tolerance test should be used instead.

For people already diagnosed with diabetes, a target HbA1c is typically set between 48–53 mmol/mol (6.5–7.0%), though this is individualised based on patient factors such as age, comorbidities, and risk of hypoglycaemia (NICE NG28).

Understanding HbA1c is fundamental to nursing practice because it directly informs treatment decisions, medication adjustments, and patient education. A persistently elevated HbA1c indicates suboptimal glycaemic control and increases the risk of long-term complications, including:

• Microvascular damage — retinopathy, nephropathy, and peripheral neuropathy

• Macrovascular disease — increased risk of myocardial infarction and stroke

• Impaired wound healing and susceptibility to infection

For nursing students preparing for examinations, grasping the clinical significance of HbA1c is essential, as it underpins a wide range of diabetes-related questions and patient care scenarios.

Key Nursing Considerations Related to HbA1c Testing

No fasting is required for HbA1c testing, and diagnosis must be confirmed with a quality-assured laboratory method; point-of-care devices must not be used for diagnostic purposes in the UK.

From a nursing perspective, HbA1c testing requires an understanding of both its clinical utility and its limitations. One important consideration is that HbA1c results can be falsely low or falsely high in certain conditions. For example, haemolytic anaemia, sickle cell disease, or recent blood transfusions can reduce red blood cell lifespan, leading to an artificially low HbA1c reading. Conversely, iron deficiency anaemia or conditions that prolong red blood cell survival may produce falsely elevated results. Nurses must be aware of these variables when interpreting results and communicating findings to patients.

For diagnostic purposes, HbA1c must be measured using a quality-assured laboratory (IFCC-standardised) method. Point-of-care HbA1c devices are not validated for diagnosis in the UK and should not be used for this purpose, though they may have a role in monitoring in some clinical settings.

When preparing a patient for HbA1c testing, it is worth noting that no fasting is required, which distinguishes it from fasting plasma glucose tests. This makes it a more convenient and patient-friendly investigation. Blood is typically drawn via venepuncture, and results are usually available within a few days. Nurses should ensure patients understand the purpose of the test and what the results mean in the context of their ongoing diabetes management.

In asymptomatic adults where HbA1c is being used for diagnosis, an abnormal result should be confirmed with a repeat venous sample before a diagnosis of diabetes is made, in line with NICE NG28 and WHO 2011 guidance.

Patient education is a core nursing responsibility in diabetes care. Key points to communicate include:

• HbA1c does not replace daily blood glucose monitoring — both provide complementary information

• Lifestyle factors such as diet, physical activity, and medication adherence directly influence HbA1c levels

• Regular HbA1c monitoring is recommended by NICE: typically every 3–6 months until stable, then every 6 months thereafter for well-controlled patients

• Patients should be encouraged to discuss their individual HbA1c target with their GP or diabetes specialist nurse

Nurses also play a vital role in identifying patients whose HbA1c is rising despite treatment, acting as a trigger for referral or medication review. Recognising when to escalate concerns to the wider multidisciplinary team is a key patient safety competency.

Patient safety note: If a patient experiences a suspected side effect from a diabetes medicine or any other medication, this should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Common NCLEX-Style Questions Involving HbA1c

HbA1c appears in NCLEX questions covering interpretation, patient education, clinical prioritisation, and pharmacology, with key thresholds of 42, 47, and 48 mmol/mol frequently tested.

The NCLEX examination, whilst primarily a North American licensing assessment, tests nursing knowledge that is broadly applicable across international clinical settings, including the UK. HbA1c frequently appears in NCLEX-style questions because it integrates pathophysiology, pharmacology, patient education, and clinical decision-making — all core competency domains.

Typical question formats involving HbA1c include:

• Interpretation questions: A patient's HbA1c is reported as 9.5% (80 mmol/mol). Which nursing action is most appropriate? (Expected answer: inform the clinician/GP and review the current management plan)

• Priority questions: A nurse is caring for four patients with diabetes. Which HbA1c result requires the most immediate follow-up? (Candidates must identify the most clinically significant value)

• Patient education questions: A patient asks why their doctor checks HbA1c every three months. What is the best nursing response? (Expected answer: it reflects average blood sugar control over the past two to three months)

• Pharmacology-linked questions: A patient with type 2 diabetes is started on metformin. Which laboratory value should the nurse monitor to evaluate long-term treatment effectiveness? (Expected answer: HbA1c)

When answering these questions, it is helpful to remember the key threshold values used in UK practice:

• Below 42 mmol/mol (6.0%) — within the normal range

• 42–47 mmol/mol (6.0–6.4%) — non-diabetic hyperglycaemia (NDH); sometimes referred to as 'at risk' of diabetes

• 48 mmol/mol (6.5%) and above — diagnostic of diabetes (in appropriate clinical contexts, with confirmation in asymptomatic adults)

Note that the term non-diabetic hyperglycaemia (NDH) is the preferred UK term (NICE/NHS Diabetes Prevention Programme); the term 'prediabetes' is used in some international contexts but is not standard UK clinical terminology. Local laboratory reference ranges and reporting units may also vary slightly; results should always be interpreted in their clinical context.

Candidates should also be prepared to link HbA1c values to clinical consequences, such as the increased risk of complications with persistently elevated levels, and to identify appropriate nursing interventions in response to abnormal results.

Revising Diabetes Monitoring Concepts for Nursing Examinations

Effective revision links HbA1c to fasting plasma glucose, SMBG, CGM, antidiabetic pharmacology, and escalation triggers such as HbA1c at 75 mmol/mol or above or suspected DKA.

Effective revision of diabetes monitoring for nursing examinations requires a structured approach that connects individual concepts — such as HbA1c — to the broader clinical picture of diabetes management. Rather than memorising isolated facts, candidates benefit from understanding how and why each monitoring tool is used, and how results guide nursing actions.

A useful revision framework for diabetes monitoring includes:

• HbA1c — long-term glycaemic control (2–3 month average); used for diagnosis (where appropriate) and treatment evaluation

• Fasting plasma glucose — point-in-time measurement; requires an 8-hour fast

• Random blood glucose — used in symptomatic patients; a result of 11.1 mmol/L or above is diagnostic of diabetes

• Self-monitoring of blood glucose (SMBG) — daily monitoring using a glucometer; particularly important for patients on insulin or sulfonylureas

• Continuous glucose monitoring (CGM) and flash glucose monitoring — NICE recommends offering CGM or flash glucose monitoring to all adults with type 1 diabetes (NICE NG17); increasingly used in type 2 diabetes and provides real-time glucose trends

Understanding the pharmacology of antidiabetic medicines is equally important. For example, insulin lowers blood glucose by facilitating cellular uptake; metformin reduces hepatic glucose production; SGLT-2 inhibitors promote urinary glucose excretion. Knowing how these medicines work helps candidates anticipate expected changes in HbA1c and identify potential adverse effects:

Experiencing these side effects? Our pharmacists can help you navigate them →

• Hypoglycaemia — most commonly associated with insulin and sulfonylureas

• Diabetic ketoacidosis (DKA) — a risk with insulin omission or illness; SGLT-2 inhibitors carry a specific risk of euglycaemic DKA (where blood glucose may not be markedly elevated), as highlighted in MHRA Drug Safety Updates. Patients taking SGLT-2 inhibitors should be counselled about this risk and advised to seek urgent medical attention if they develop symptoms of DKA

Finally, candidates should revise when to refer or escalate in diabetes care. Situations that warrant priority review include:

• HbA1c remaining at 75 mmol/mol (9%) or above despite treatment — arrange priority review, consider intensification of therapy, and refer to a specialist diabetes service if appropriate

• Recurrent hypoglycaemic episodes

• Symptoms suggestive of diabetic ketoacidosis (DKA) — polyuria, polydipsia, vomiting, and altered consciousness — which require urgent assessment and management

Note that a persistently elevated HbA1c alone, whilst clinically significant, does not in itself constitute a medical emergency; reserve urgent escalation for acute metabolic deterioration such as suspected DKA or hyperosmolar hyperglycaemic state (HHS).

Approaching revision holistically — linking HbA1c to diagnosis, monitoring, medication, and patient safety — will equip nursing candidates with the depth of knowledge needed to answer examination questions with confidence and accuracy.

Frequently Asked Questions